Abzena Signs ADC Deal
Abzena, a life sciences group providing services and technologies to enable development and manufacture of biopharmaceutical products, has signed a licensing deal for its site-specific ThioBridge antibody drug conjugate (ADC) linker technology.
Abzena will receive an initial license and target nomination fee and has the potential to receive further license fees and milestone payments of up to $150 million if the partner develops a product for each of three designated targets with the ThioBridge technology, as well as royalties on the sale of ThioBridge ADC products developed under this agreement.
ThioBridge is Abzena's proprietary ADC linker technology, which links antibodies and other proteins to drugs. Following a collaborative research program jointly conducted by Abzena and its partner for the evaluation of ThioBridge, during which multiple ADC product candidates were evaluated for efficacy and safety in preclinical models, the undisclosed biotech company selected a lead product for further development.